• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国胃肠胰神经内分泌肿瘤的发病趋势。

Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.

机构信息

Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1. doi: 10.1016/j.cgh.2018.12.017. Epub 2018 Dec 20.

DOI:10.1016/j.cgh.2018.12.017
PMID:30580091
Abstract

BACKGROUND & AIMS: Although multiple studies have reported an increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) over the past decades, there are limited national data on recent trends. Using a population-based registry, we evaluated GEP-NET incidence trends in the United States population from 1975 through 2012, based on age, calendar year at diagnosis, and year of birth.

METHODS

GEP-NET cases from 1975 through 2012 were identified from the most recent version of the Surveillance, Epidemiology, and End Results registry using histologic and site codes. We calculated overall annual incidence, age-adjusted incidence (number of cases per 100,000), annual percent change (APC), and average APC by 5-year age intervals. We also evaluated the incidence rates by age, period, and birth year cohorts.

RESULTS

We identified 22,744 patients with GEP-NETs. In adults 25-39 years old, GEP-NET incidence rates decreased from the mid-1970s to the early 1980s, then increased until 2012. In adults ages 40 years and older or young adults ages 15-24 years, incidence rates generally increased continuously from 1975 through 2012. Adults ages 40-69 years had the most rapid increases in average APC (approximately 4%-6% per year). Overall incidence rates were highest in adults 70-84 years old. Since the inception of the Surveillance, Epidemiology, and End Results registry, GEP-NET incidence has increased in consecutive birth cohorts.

CONCLUSION

The incidence of GEP-NET continues to increase-particularly in older adults. More recent generations have had higher GEP-NET incidence rates than more distant generations.

摘要

背景与目的

尽管过去几十年的多项研究报告称,胃肠胰神经内分泌肿瘤(GEP-NETs)的发病率不断上升,但有关近期趋势的全国性数据有限。本研究利用基于人群的登记处,根据年龄、诊断时的日历年份和出生年份,评估了美国人群中 1975 年至 2012 年 GEP-NET 的发病率趋势。

方法

使用最新版的监测、流行病学和最终结果登记处的组织学和部位代码,从 1975 年至 2012 年确定 GEP-NET 病例。我们计算了总体年度发病率、年龄调整发病率(每 10 万人中的病例数)、年度百分比变化(APC)和 5 年年龄间隔的平均 APC。我们还根据年龄、时期和出生年份队列评估了发病率。

结果

我们确定了 22744 例 GEP-NET 患者。在 25-39 岁的成年人中,GEP-NET 发病率从 20 世纪 70 年代中期到 80 年代初下降,然后在 2012 年之前上升。在 40 岁及以上的成年人或 15-24 岁的年轻人中,发病率通常从 1975 年持续上升至 2012 年。40-69 岁的成年人的平均 APC 增长率最快(约每年 4%-6%)。70-84 岁的成年人总体发病率最高。自监测、流行病学和最终结果登记处成立以来,GEP-NET 的发病率在连续的出生队列中不断增加。

结论

GEP-NET 的发病率持续上升,尤其是在老年人中。最近几代人的 GEP-NET 发病率高于更遥远的几代人。

相似文献

1
Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.美国胃肠胰神经内分泌肿瘤的发病趋势。
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1. doi: 10.1016/j.cgh.2018.12.017. Epub 2018 Dec 20.
2
Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.美国胃肠胰神经内分泌肿瘤患者总体生存的流行病学趋势及相关因素。
JAMA Netw Open. 2021 Sep 1;4(9):e2124750. doi: 10.1001/jamanetworkopen.2021.24750.
3
Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.胃肠胰神经内分泌肿瘤合并糖尿病患者的生存状况。
Pancreas. 2021 Oct 1;50(9):1293-1297. doi: 10.1097/MPA.0000000000001911.
4
Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?十二指肠神经内分泌肿瘤发病率上升:是惰性疾病的偶然发现?
Surgery. 2015 Aug;158(2):466-71. doi: 10.1016/j.surg.2015.03.042. Epub 2015 May 23.
5
Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.日本胃-肠-胰神经内分泌肿瘤(GEP-NEN)患者的最新流行病学:一项基于人群的研究。
BMC Cancer. 2020 Nov 14;20(1):1104. doi: 10.1186/s12885-020-07581-y.
6
Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.基于单一机构数据的成都市1400万人口胃肠胰神经内分泌肿瘤的流行病学特征
Asia Pac J Clin Oncol. 2016 Sep;12(3):284-8. doi: 10.1111/ajco.12498. Epub 2016 May 12.
7
Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.临床上检测到的胃肠胰神经内分泌肿瘤正在增加:德国的流行病学变化。
World J Gastroenterol. 2013 Dec 21;19(47):9012-9. doi: 10.3748/wjg.v19.i47.9012.
8
Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.拉脱维亚三级转诊医院对胃肠胰神经内分泌肿瘤的流行病学数据及治疗见解
World J Surg. 2020 Feb;44(2):585-593. doi: 10.1007/s00268-019-05219-0.
9
Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.胃肠胰神经内分泌肿瘤的发病率:文献系统综述。
Endocr Relat Cancer. 2014 May 6;21(3):R153-63. doi: 10.1530/ERC-13-0125. Print 2014 Jun.
10
The epidemiology of gastroenteropancreatic neuroendocrine tumors.胃肠胰神经内分泌肿瘤的流行病学。
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005.

引用本文的文献

1
Case report of carcinoid syndrome with multi-organ involvement.类癌综合征伴多器官受累的病例报告。
J Gastrointest Oncol. 2025 Aug 30;16(4):1756-1762. doi: 10.21037/jgo-2025-26. Epub 2025 Aug 8.
2
Radiotherapy versus no radiotherapy for rectal neuroendocrine carcinoma patients treated with surgery and chemotherapy: a population-based cohort study.手术联合化疗的直肠神经内分泌癌患者接受放疗与不接受放疗的比较:一项基于人群的队列研究
Discov Oncol. 2025 Aug 15;16(1):1559. doi: 10.1007/s12672-025-03418-x.
3
Epidemiological insights and survival patterns in neuroendocrine neoplasia: a geographic perspective.
神经内分泌肿瘤的流行病学见解与生存模式:地域视角
Endocr Oncol. 2025 Aug 5;5(1):e250039. doi: 10.1530/EO-25-0039. eCollection 2025 Jan.
4
Automated machine learning predicts liver metastases in patients with early-onset gastroenteropancreatic neuroendocrine tumors.自动机器学习可预测早发性胃肠胰神经内分泌肿瘤患者的肝转移情况。
J Gastrointest Oncol. 2025 Jun 30;16(3):937-949. doi: 10.21037/jgo-2024-946. Epub 2025 Jun 18.
5
Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.大小至关重要:确定直肠神经内分泌肿瘤的临界值以预测复发并规范监测指南。
Dig Endosc. 2025 Sep;37(9):962-971. doi: 10.1111/den.15056. Epub 2025 Jun 10.
6
Metabolic changes in neuroendocrine neoplasms.神经内分泌肿瘤中的代谢变化。
Cell Mol Life Sci. 2025 May 16;82(1):205. doi: 10.1007/s00018-025-05656-2.
7
A single center retrospective analysis of feasibility of diagnostic endoscopic resection for grade 1 or 2 gastric neuroendocrine tumors.单中心回顾性分析1级或2级胃神经内分泌肿瘤诊断性内镜切除的可行性。
Sci Rep. 2025 May 10;15(1):16315. doi: 10.1038/s41598-025-99791-2.
8
A systematic review on endoscopic ultrasound in gastric neuroendocrine neoplasms: guidelines outpacing evidence.关于内镜超声在胃神经内分泌肿瘤中的系统评价:指南领先于证据
Clin Endosc. 2025 Jul;58(4):525-532. doi: 10.5946/ce.2024.343. Epub 2025 Apr 24.
9
Safety and dosimetry of [Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study.[镥]镥-多柔比星-奥曲肽在生长抑素受体阳性的胃肠胰神经内分泌肿瘤、嗜铬细胞瘤和副神经节瘤青少年患者中的安全性和剂量测定:II期NETTER-P研究的初步分析
Eur J Nucl Med Mol Imaging. 2025 Apr 8. doi: 10.1007/s00259-025-07246-7.
10
miRNA profile in pancreatic neuroendocrine tumors: Preliminary results.胰腺神经内分泌肿瘤中的微小RNA谱:初步结果。
Sci Prog. 2025 Jan-Mar;108(1):368504251326864. doi: 10.1177/00368504251326864. Epub 2025 Mar 28.